Rigel Pharmaceuticals, Inc.

DB:RI2 Stock Report

Market Cap: €279.4m

Rigel Pharmaceuticals Management

Management criteria checks 3/4

Rigel Pharmaceuticals' CEO is Raul Rodriguez, appointed in May 2010, has a tenure of 14.67 years. total yearly compensation is $3.44M, comprised of 21.2% salary and 78.8% bonuses, including company stock and options. directly owns 0.74% of the company’s shares, worth €2.08M. The average tenure of the management team and the board of directors is 3.7 years and 6.5 years respectively.

Key information

Raul Rodriguez

Chief executive officer

US$3.4m

Total compensation

CEO salary percentage21.2%
CEO tenure14.7yrs
CEO ownership0.7%
Management average tenure3.7yrs
Board average tenure6.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Raul Rodriguez's remuneration changed compared to Rigel Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$4m

Jun 30 2024n/an/a

-US$14m

Mar 31 2024n/an/a

-US$20m

Dec 31 2023US$3mUS$728k

-US$25m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023n/an/a

-US$38m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$3mUS$700k

-US$59m

Sep 30 2022n/an/a

-US$83m

Jun 30 2022n/an/a

-US$85m

Mar 31 2022n/an/a

-US$85m

Dec 31 2021US$3mUS$662k

-US$18m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$3mUS$662k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$3mUS$649k

-US$67m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$59m

Mar 31 2019n/an/a

-US$64m

Dec 31 2018US$4mUS$637k

-US$70m

Compensation vs Market: Raul's total compensation ($USD3.44M) is above average for companies of similar size in the German market ($USD890.74K).

Compensation vs Earnings: Raul's compensation has been consistent with company performance over the past year.

CEO

Raul Rodriguez (63 yo)

14.7yrs

Tenure

US$3,440,790

Compensation

Mr. Raul R. Rodriguez has been the Chief Executive Officer and Director of Rigel Pharmaceuticals, Inc., since November 2014 and its President since May 2010. Mr. Rodriguez served as Chief Operating Officer...

Leadership Team

NamePositionTenureCompensationOwnership
Raul Rodriguez
President14.7yrsUS$3.44m0.74%
€ 2.1m
Dean Schorno
Executive VP & CFO6.7yrsUS$1.21m0.069%
€ 192.9k
Raymond Furey
Executive VP2.1yrsUS$683.00k0.0028%
€ 7.9k
David Santos
Executive VP & Chief Commercial Officer4.4yrsUS$1.34m0.031%
€ 87.4k
Julie Patel
Senior VP of Human Resources3yrsno datano data
Esteban Masuda
Executive Vice President of Research8.3yrsUS$796.09kno data
Joseph Lasaga
Executive VP & Chief Business Officerless than a yearno datano data
Lisa Rojkjaer
Executive VP & Chief Medical Officerless than a yearno datano data
Tarek Sallam
Vice President of Marketingno datano datano data

3.7yrs

Average Tenure

61yo

Average Age

Experienced Management: RI2's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Raul Rodriguez
President10.2yrsUS$3.44m0.74%
€ 2.1m
Walter Moos
Independent Director27.8yrsUS$138.58k0.044%
€ 122.5k
Jane Wasman
Independent Director5.8yrsUS$145.58k0.043%
€ 119.0k
Gregory Lapointe
Independent Chairman of the Board7.2yrsUS$190.58k0.043%
€ 119.0k
Kamil Jackson
Independent Director3.1yrsUS$140.58k0.025%
€ 69.4k
Alison Hannah
Independent Director3.7yrsUS$212.98k0.032%
€ 89.2k

6.5yrs

Average Tenure

65yo

Average Age

Experienced Board: RI2's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 09:09
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rigel Pharmaceuticals, Inc. is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBarclays
Clarence PowellBMO Capital Markets Equity Research
James BirchenoughBMO Capital Markets Equity Research